Mosaic reported a strong third quarter for 2025, with net income rising to $411 million and adjusted EBITDA increasing 80% year-over-year to $806 million, driven by higher prices across all segments and robust performance in Brazil. Despite these gains, operational challenges persist in the phosphate segment, where management is working to restore 'institutional knowledge' and consistency after years of low utilization, achieving a trailing three-month production rate of 1.8 million tonnes. Cash flow was significantly impacted by a $400 million build in working capital, resulting in operating cash flow of just $229 million and effectively zero free cash flow for the year to date. Looking ahead, management remains highly confident in a strong finish to 2025 and a 'promising 2026,' underpinned by $250 million in targeted cost savings, a tightening global phosphate supply market due to Chinese export restrictions, and the anticipation that Mosaic Biosciences will turn EBITDA positive in Q4.
| Metric | Value | Change |
|---|---|---|
| Net Income (Q3 2025) | $411 million | +$289 million vs prior year |
| Adjusted EBITDA (Q3 2025) | $806 million | +$358 million vs prior year |
| Phosphate Production (Trailing 3-month) | 1.8 million tonnes | Sequential improvement |
| Potash Cash Cost | $71 per tonne | Down from $75 in Q2 |
| Operating Cash Flow | $229 million | Impacted by >$400M working capital build |
| Cost Savings Achieved | $150 million | On track for $250M by end of 2026 |
Mosaic is executing a significant capital reallocation strategy, streamlining its portfolio to focus on high-return assets. The company completed the sale of the Taquari potash mine for $27 million and the idle Patos de Minas phosphate mine for $111 million. These divestitures are not just about raising cash but eliminating future capital expenditures (CapEx) and asset retirement obligations (AROs). Management stated these moves avoid 'significant capital investments' and transfer liabilities, signaling a strategic pivot to free up resources for core operations and shareholder returns by 2026.
The operational turnaround in Phosphates has shifted from mechanical repair to 'operational discipline.' Management reported three consecutive quarters of production improvement, reaching a 1.8 million tonne run rate. The strategic signal here is the focus on 'institutional knowledge' and workforce consistency rather than just asset reliability. If successful, this leverages high fixed-cost absorption; CFO Luciano Pires noted that moving from 6.4M to 8M tonnes could theoretically improve EBITDA by over 50% due to operational leverage.
Mosaic Biosciences is emerging as a key growth diversification engine. Revenues for the first nine months 'more than doubled' year-over-year, and the segment is expected to contribute positively to consolidated Adjusted EBITDA starting in Q4 2025. This initiative leverages Mosaic's existing distribution network to capture higher-margin biological product demand, which is growing rapidly in China and expected to expand in India.
Global supply constraints are tightening the phosphate market, creating a favorable pricing environment. Jenny Wang highlighted that Chinese phosphate exports are down 1.5 million tonnes in 2025 and are expected to remain restricted. Concurrently, LFP battery demand for industrial phosphate grew over 40% year-over-year in China. This supply-demand imbalance supports 'historically elevated stripping margins' and insulates Mosaic from near-term demand softness in the Americas.
Mosaic is experiencing a severe cash flow conversion disconnect. Despite generating $806 million in Adjusted EBITDA, Operating Cash Flow was only $229 million due to a >$400 million increase in working capital, driven by inventory builds. CFO Luciano Pires admitted that free cash flow for 2025 is 'very close to zero.' This liquidity crunch forced the deferral of dividends and buybacks until 2026, indicating that the strong earnings are not yet translating to shareholder liquidity.
Operational execution risk remains high in the Phosphate segment. CEO Bruce Bodine admitted that the team has 'lost some muscle memory' after 5 years of low utilization, leading to inconsistency between 'good days and bad days.' He noted that 'bad days' are now caused by 'operational decision-making at the front line' rather than equipment failure. This human element introduces volatility and makes the 2.0 million tonne production target harder to guarantee compared to purely mechanical fixes.
The Brazilian business faces a deteriorating credit environment and margin pressure. While Mosaic Fertilizantes beat EBITDA expectations in Q3 ($241M vs $200M guidance), management warned of a 'significant drop' in Q4 due to compressed distribution margins ($20/tonne vs $30-$40 target) and a shift to lower-margin products. The reliance on government payments and farmer creditworthiness in Brazil adds a layer of macroeconomic risk to near-term earnings.
Input cost inflation is threatening margins. Sulfur and ammonia prices are rising due to geopolitical factors (Russian export bans, refinery attacks). Management noted that stripping margins are coming down from the '5-handle' to the 'low 4s or upper 3s.' If these raw material costs persist while farmer affordability remains weak, Mosaic may struggle to pass these costs on to customers, potentially compressing Q4 profitability.
Overall: Management conveyed a tone of resilient confidence mixed with operational transparency. CEO Bruce Bodine was candid about the 'longer than anticipated' timeline to fix phosphate operations, shifting the narrative from mechanical repairs to rebuilding human 'muscle memory.' While acknowledging near-term cash flow headwinds and Brazilian credit challenges, the team remained bullish on the 2026 outlook, emphasizing that the 'structural asset health issue' is resolved and that they are 'highly confident' in finishing the year strong.
Confidence: HIGH - Management's confidence was anchored in the 80% EBITDA growth and the resolution of major asset health issues. While they hedged on immediate quarterly volatility due to 'very high' uncertainties in Brazil, they provided specific, data-backed reasons for their optimism regarding 2026 cash flow conversion and global supply deficits.
1.7 million to 1.9 million tonnes (risk to downside due to demand deferral)
Expected to be higher than Q4 2024
Low to mid-$70s per tonne
Extraordinary dividends or buybacks deferred to 2026
Positive contribution expected beginning Q4 2025
Hedging & Uncertainty: Management employed significant hedging regarding the immediate future, particularly concerning the Brazilian market and Q4 guidance. Phrases like 'uncertainties in volumes, prices and margins are very high' and 'EBITDA could be in a wide range' indicate low visibility for the next quarter. They also used temporal hedges to push positive outcomes to 2026, stating that free cash flow improvement 'is expected to' and dividends are deferred 'to 2026.' However, they were less hedged on the long-term structural supply story, confidently stating that demand is 'constrained by supply' and that Chinese exports 'are expected to decrease.'
"Taking a little longer than anticipated" - Bruce Bodine, President and CEO
"Lost some muscle memory" - Bruce Bodine, President and CEO
"Demand is constrained by supply" - Jenny Wang, Executive Vice President, Commercial
"Free cash flow for '25, which is very close to zero" - Luciano Pires, Executive Vice President and CFO
"We are highly confident in our ability to finish the year on a high note" - Bruce Bodine, President and CEO
"Clean quarter" - Bruce Bodine, President and CEO
"Risk to the downside" - Bruce Bodine, President and CEO
Analyst Sentiment: Analysts were focused on the operational reliability of the phosphate assets and the sustainability of the production ramp. There was skepticism about the 'good day vs bad day' volatility and a keen interest in the cadence of improvement heading into 2026. Questions also probed the disconnect between strong EBITDA and weak cash flow conversion.
Management Responses: Management was transparent, acknowledging that the timeline to restore 'normalized' production was 'taking a little longer than anticipated' due to workforce 'muscle memory' issues rather than structural asset failures. They provided detailed technical explanations for cost variances and production hiccups, reinforcing their credibility while managing expectations for the immediate quarter.
Phosphate operational stability and the specific causes of 'bad days' (workforce turnover vs. mechanical issues).
Cash flow conversion rates and the specific drivers of the working capital build (inventories).
The outlook for the Brazilian market, specifically the impact of credit availability on farmer buying.
Input cost inflation, specifically sulfur and ammonia, and the impact on stripping margins.
The potential for demand deferral from Q4 to Q1 due to weather and government payments.
Mosaic presents a compelling turnaround story heading into 2026, underpinned by a tightening global phosphate supply chain and significant operational leverage. While Q3 2025 demonstrated strong top-line recovery (Adj. EBITDA +80% YoY) and pricing power, the investment thesis rests on the successful normalization of phosphate operations. The shift from mechanical repairs to 'institutional knowledge' rebuilding suggests the worst of the operational disruptions are over, though execution risk remains. The current valuation appears to discount the 2026 inflection, where management forecasts a significant cash flow conversion improvement (to 25-30% of EBITDA) as working capital normalizes and production volumes sustain at the 1.8M+ tonne level. The deferral of buybacks to 2026 is prudent given the near-term cash flow squeeze but highlights the current liquidity constraint. Investors should look past the near-term 'zero free cash flow' of 2025 and focus on the structural supply deficits and margin expansion potential in 2026.
Chinese phosphate exports are down 1.5 million tonnes in 2025 and are expected to remain restricted due to domestic demand growth and export approval pullbacks. This creates a structural supply deficit that supports elevated global prices.
Farmers in North America and Brazil are facing tighter credit and economic uncertainty, leading to cautious buying behavior and potential demand deferral from Q4 to Q1.
LFP battery demand continues to surge, with Chinese production up over 40% year-over-year, providing a new and growing demand source for industrial phosphate.
Geopolitical factors, including the Russian sulfur export ban and refinery attacks, are driving up sulfur and ammonia costs, which pressures fertilizer stripping margins in the near term.